Fimepinostat is a dual PI3K and HDAC inhibitor. Fimepinostat is able to enhance antitumor activity when combined with standard of care agents to inhibits cell growth in a panel of colon, pancreatic, non-small cell lung cancer (NSCLC), and multiple myeloma cells. Reagent grade, for research purpose.
Usually ships within 24 hours.